UKi2S is an early-stage venture capital firm that invests in innovations emerging from the UK's publicly funded science and knowledge base, specializing in engineering biology, defence & security, fusion energy, and space. Their strategy involves providing pre-seed and seed capital, typically between £100k and £500k, with the aim of facilitating sustainable growth, enhancing societal health and security, and delivering economic gains.
57% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Their most common stage is seed (86% of deals). Average disclosed round size is $5.6M (across 6 rounds with reported amounts).
Portfolio
7
Fund Size
$102M
Top Stage
Seed
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 CamGene Therapeutics | Seed | — | Nov 2025 |
 Spaceflux | Seed | $6.1M | Jul 2025 |
| IiFAST Diagnostics | Seed | $5.9M | Nov 2024 |
 Antiverse | Seed | $4.2M | Oct 2024 |
| SSOLASTA Bio | Series A | $14M | Sep 2024 |
 Mirico | Seed | $2M | Jun 2024 |
| SSOLASTA Bio | Seed | $1.5M | Aug 2021 |
Top Co-Investors
Last updated: 8 March 2026